Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug 2;11(15):e026774.
doi: 10.1161/JAHA.122.026774. Epub 2022 Jul 29.

SGLT2 Inhibitors-A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling

Takashi Yagi  1 , Gopi K Kolluru  1
Affiliations
Editorial

SGLT2 Inhibitors-A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling

Takashi Yagi et al. J Am Heart Assoc. .
No abstract available

Keywords: Editorials; heart failure; high blood pressure; hypertension; mechanisms; myocardial infarction.

PubMed Disclaimer

Comment on

References

    1. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease. Circulation. 2021;143:1157–1172. doi: 10.1161/CIRCULATIONAHA.120.050686 - DOI - PMC - PubMed
    1. Borrelli S, Provenzano M, Gagliardi I, Michael A, Liberti ME, De Nicola L, Conte G, Garofalo C, Andreucci M. Sodium intake and chronic kidney disease. Int J Mol Sci. 2020;21:4744. doi: 10.3390/ijms21134744 - DOI - PMC - PubMed
    1. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285–292. doi: 10.1161/hypertensionaha.119.14240 - DOI - PMC - PubMed
    1. Aguilar‐Gallardo JS, Correa A, Contreras JP. Cardio‐renal benefits of sodium‐glucose co‐transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2022;8:311–321. doi: 10.1093/ehjcvp/pvab056 - DOI - PubMed
    1. Wan N, Fujisawa Y, Kobara H, Masaki T, Nakano D, Rahman A, Nishiyama A. Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease. Hypertens Res. 2020;43:492–499. doi: 10.1038/s41440-020-0410-8 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources